Did you miss the analysis of the recent US Presidential Executive Order on US drug pricing at ISPOR 2025 in Montreal? Enjoy the analysis below and provide your thoughts.
Here is the analysis

🌟Was one of the most popular topics discussed from the keynote to the hallway discussions and cocktails
🌟Keynote discussion started with the reading of the executive order, which drew skepticism from the experts and the attendees alike
🌟The main opinion was that foreign drug prices are determined through value assessments done by those countries and careful evaluations of drugs applied. It’s misguided and naive to assume that other countries will raise their prices as we lower ours, and it shows a real lack of understanding about how other countries do HTA and make decisions.
🌟The order is based on a misconception that somehow, pharmaceutical companies can strong-arm other governments to negotiate higher prices.
🌟Pharmaceutical manufacturers are bound by contracts, which’ve been established, and if they are not met, they are in breach of contract
🌟One net effect of this order could be that the Globalist prices go up, and confidential prices negotiated with these countries stay the same. There might be a political victory, but the prices don’t fall.

 
Many additional discussions with Clinakos Inc. on HEOR, and RWE reflected the similar sentiments.